Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical technology provider Kinetic Concepts (NYSE: KCI) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Kinetic's business and see what CAPS investors are saying about the stock right now.

Kinetic facts

Headquarters (founded)

San Antonio (1976)

Market Cap

$2.6 billion


Health-care equipment

Trailing-12-Month Revenue

$2.01 billion


CEO Catherine Burzik (since 2006)

CFO Martin Landon (since 2002)

Return on Equity (average, past 3 years)



$247.07 million / $1.2 billion


Stryker (NYSE: SYK)

Smith & Nephew (NYSE: SNN)

Covidien (NYSE: COV)

C.R. Bard (NYSE: BCR)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 97% of the 716 members who have rated Kinetic believe the stock will outperform the S&P 500 going forward. These bulls include trurl9 and ArfytheSeal.

This past summer, trurl9 highlighted the stock for its healing powers: "[Kinetic's] innovative wound care products are a boon to doctors and patients. Expansion into Europe and Japan. [Kinetic] is successfully defending its patents and is willing to do so. Management keeps [Kinetic] moving forward and gaining ground."

In fact, Kinetic is the dominant force in negative-pressure wound therapy, covering about a third of the advanced wounds in the United States. Unfortunately, looming patent expirations on its vacuum-assisted closure  technology, coupled with increasingly fierce competition, pose a threat to Kinetic's virtual monopoly. Nevertheless, Fools remain confident that Kinetic's ability to innovate will keep it ahead of the wound therapy pack for quite some time. Of course, with Kinetic currently sporting a forward P/E of 8.1 -- representing a clear discount to main rivals Smith & Nephew (12.1), Stryker (13.8), Covidien (11.5), and 3M (13.8) -- investors won't have to pay big price to make that bet.

CAPS member ArfytheSeal elaborates on the bargain:

The company is a manufacturer of specialty hospital beds and other medical equipment (such as wound care / healing devices). The firm has been exhibiting long-term growth and grades at an Enterprise Value to EBITDA of under 6x. Further, the p/e ratio is just over 10x. Free cash flow (Net Cash After Operations less Capex) divided by market cap is 13%, an excellent cash on cash return.

What do you think about Kinetic, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Covidien and Stryker are Motley Fool Inside Value picks. The Fool owns shares of Kinetic. Try any of our Foolish newsletter services free for 30 days.

True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community. The Fool's disclosure policy always gets a perfect score.